Insulet Corp. reported it has entered into a development agreement with Eli Lilly and company (Lilly) to develop a new version of Insulet's OmniPod tubeless insulin delivery system, specifically designed to deliverLilly's Humalog 200 units/mL insulin. The company noted that Humalog U200 is a concentrated form of insulin used by higher insulin-requiring patients with diabetes that provides the same dose of insulin in half the volume of Lilly's Humalog U100 insulin.

Insulet is partnering with Lilly on a clinical development program designed to evaluate the use of the Humalog U200 insulin formulation in Insulet's leading OmniPod tubeless insulin delivery system.